Isis Pharmaceuticals (ISIS) initiates phase 2 studies evaluating ISIS-FXIRx in patients...


Isis Pharmaceuticals (ISIS) initiates phase 2 studies evaluating ISIS-FXIRx in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty. The drug inhibits coagulation produced in the liver which is involved in the formation of clots, and the study will evaluate its effectiveness in reducing the number of thrombotic events - a potentially serious problem - in patients after surgery without increasing bleeding.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs